Cargando…
Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial
BACKGROUND: Previous large trials of vitamin D for prevention of fractures and other disease outcomes have reported conflicting results, possibly because the doses tested were insufficient to maintain optimum blood levels of vitamin D (25[OH]D) predicted by the observational studies. This report des...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier/North Holland Biomedical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387549/ https://www.ncbi.nlm.nih.gov/pubmed/25721698 http://dx.doi.org/10.1016/j.maturitas.2015.01.013 |
_version_ | 1782365284022091776 |
---|---|
author | Clarke, Robert Newman, Connie Tomson, Joseph Hin, Harold Kurien, Rijo Cox, Jolyon Lay, Michael Sayer, Jenny Hill, Michael Emberson, Jonathan Armitage, Jane |
author_facet | Clarke, Robert Newman, Connie Tomson, Joseph Hin, Harold Kurien, Rijo Cox, Jolyon Lay, Michael Sayer, Jenny Hill, Michael Emberson, Jonathan Armitage, Jane |
author_sort | Clarke, Robert |
collection | PubMed |
description | BACKGROUND: Previous large trials of vitamin D for prevention of fractures and other disease outcomes have reported conflicting results, possibly because the doses tested were insufficient to maintain optimum blood levels of vitamin D (25[OH]D) predicted by the observational studies. This report describes the design and baseline characteristics of the BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial which aims to establish the best dose of vitamin D to assess in a future large outcome trial. METHODS: The BEST-D trial will compare the biochemical and other effects of daily dietary supplementation with 100 μg or 50 μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90 nmol/L between participants allocated 100 μg and participants allocated 50 μg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. RESULTS: About one-third of eligible participants agreed to participate in the trial. The mean age was 72 (SD 6) years with equal numbers of men and women. About one third reported a prior history of fracture or hypertension, one-fifth reported a prior cardiovascular event, and one tenth reported diabetes or a fall in the previous 6 months. CONCLUSIONS: The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer. |
format | Online Article Text |
id | pubmed-4387549 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Elsevier/North Holland Biomedical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43875492015-04-09 Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial Clarke, Robert Newman, Connie Tomson, Joseph Hin, Harold Kurien, Rijo Cox, Jolyon Lay, Michael Sayer, Jenny Hill, Michael Emberson, Jonathan Armitage, Jane Maturitas Article BACKGROUND: Previous large trials of vitamin D for prevention of fractures and other disease outcomes have reported conflicting results, possibly because the doses tested were insufficient to maintain optimum blood levels of vitamin D (25[OH]D) predicted by the observational studies. This report describes the design and baseline characteristics of the BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial which aims to establish the best dose of vitamin D to assess in a future large outcome trial. METHODS: The BEST-D trial will compare the biochemical and other effects of daily dietary supplementation with 100 μg or 50 μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90 nmol/L between participants allocated 100 μg and participants allocated 50 μg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. RESULTS: About one-third of eligible participants agreed to participate in the trial. The mean age was 72 (SD 6) years with equal numbers of men and women. About one third reported a prior history of fracture or hypertension, one-fifth reported a prior cardiovascular event, and one tenth reported diabetes or a fall in the previous 6 months. CONCLUSIONS: The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer. Elsevier/North Holland Biomedical Press 2015-04 /pmc/articles/PMC4387549/ /pubmed/25721698 http://dx.doi.org/10.1016/j.maturitas.2015.01.013 Text en Crown Copyright © Published by Elsevier Ireland Ltd. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Clarke, Robert Newman, Connie Tomson, Joseph Hin, Harold Kurien, Rijo Cox, Jolyon Lay, Michael Sayer, Jenny Hill, Michael Emberson, Jonathan Armitage, Jane Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial |
title | Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial |
title_full | Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial |
title_fullStr | Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial |
title_full_unstemmed | Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial |
title_short | Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial |
title_sort | estimation of the optimum dose of vitamin d for disease prevention in older people: rationale, design and baseline characteristics of the best-d trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387549/ https://www.ncbi.nlm.nih.gov/pubmed/25721698 http://dx.doi.org/10.1016/j.maturitas.2015.01.013 |
work_keys_str_mv | AT clarkerobert estimationoftheoptimumdoseofvitamindfordiseasepreventioninolderpeoplerationaledesignandbaselinecharacteristicsofthebestdtrial AT newmanconnie estimationoftheoptimumdoseofvitamindfordiseasepreventioninolderpeoplerationaledesignandbaselinecharacteristicsofthebestdtrial AT tomsonjoseph estimationoftheoptimumdoseofvitamindfordiseasepreventioninolderpeoplerationaledesignandbaselinecharacteristicsofthebestdtrial AT hinharold estimationoftheoptimumdoseofvitamindfordiseasepreventioninolderpeoplerationaledesignandbaselinecharacteristicsofthebestdtrial AT kurienrijo estimationoftheoptimumdoseofvitamindfordiseasepreventioninolderpeoplerationaledesignandbaselinecharacteristicsofthebestdtrial AT coxjolyon estimationoftheoptimumdoseofvitamindfordiseasepreventioninolderpeoplerationaledesignandbaselinecharacteristicsofthebestdtrial AT laymichael estimationoftheoptimumdoseofvitamindfordiseasepreventioninolderpeoplerationaledesignandbaselinecharacteristicsofthebestdtrial AT sayerjenny estimationoftheoptimumdoseofvitamindfordiseasepreventioninolderpeoplerationaledesignandbaselinecharacteristicsofthebestdtrial AT hillmichael estimationoftheoptimumdoseofvitamindfordiseasepreventioninolderpeoplerationaledesignandbaselinecharacteristicsofthebestdtrial AT embersonjonathan estimationoftheoptimumdoseofvitamindfordiseasepreventioninolderpeoplerationaledesignandbaselinecharacteristicsofthebestdtrial AT armitagejane estimationoftheoptimumdoseofvitamindfordiseasepreventioninolderpeoplerationaledesignandbaselinecharacteristicsofthebestdtrial |